Boehringer Ingelheim Pharma GmbH & Co. KG has identified stimulator of interferon genes protein (STING; TMEM173) agonists reported to be useful for the treatment of cancer, allergy, autoimmune disease, inflammatory disorders and infections.

Shanghai Yidi Biotechnology Co. Ltd. has synthesized peptide-based nitrile compounds acting as dipeptidyl peptidase 1 (DPP-1, cathepsin C) inhibitors reported to be useful for the treatment of cancer, infections, and respiratory, metabolic, cardiovascular, cerebrovascular and autoimmune diseases.

Suzhou Genhouse Bio Co. Ltd. has disclosed transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) interaction inhibitors reported to be useful for the treatment of fibrosis, skin lesions, tissue repair and regeneration and cancer.

Bristol Myers Squibb Co. and Celgene Corp. have described MAP kinase-activated protein kinase 2 (MAPKAPK2; MK2) inhibitors reported to be useful for the treatment of inflammation, cancer, fibrosis, autoimmune disorders, cardiovascular disorders, metabolic disorders and cerebrovascular disorders.

Inversago Pharma Inc. has divulged cannabinoid CB1 receptor antagonists reported to be useful for the treatment of cancer, diabetes, fibrosis, hypertension, irritable bowel syndrome, metabolic syndrome, alopecia and Prader-Willi syndrome.

Shanghai Shenshi Wise Technology Co. Ltd. has identified potassium voltage-gated channel subfamily A member 3 (KCNA3) channel blockers reported to be useful for the treatment of inflammatory and immunological disorders.

Artivila Biopharma Co. Ltd. has synthesized macrocyclic compounds acting as cyclin-dependent kinase 9 (CDK9) inhibitors reported to be useful for the treatment of cancer.

Boehringer Ingelheim Pharma GmbH & Co. KG has disclosed dioxane derivatives acting as mGluR4 negative allosteric modulators reported to be useful for the treatment of neurodegeneration, metabolic disease, cancer, psychiatric disorders and neurological disorders.

Cybin Irl Ltd. has described phenethylamine compounds acting as 5-HT2 receptor agonists reported to be useful for the treatment of lung diseases, cardiovascular disorders, inflammatory disorders, psychiatric disorders and neurological disorders.

Neurocrine Biosciences Inc. has divulged G protein-coupled receptor GPR52 modulators reported to be useful for the treatment of schizophrenia, obsessive-compulsive disorder, attention deficit hyperactivity disorder, bipolar disorder, vascular cognitive impairment, and Alzheimer’s, Parkinson’s and Huntington’s diseases, among other neurological disorders.